Evaluation of efficacy of glatiramer acetate treatment for multiple sclerosis in Japan

被引：0
|
作者：
Okamoto, T. [1 ,2 ]
Lin, Y. [1 ,2 ,3 ]
Araki, M. [1 ,2 ,3 ]
Sato, W. [2 ,3 ]
Takahashi, Y. [1 ]
Yamamura, T. [2 ,3 ]
机构：
[1] Natl Ctr Hosp, Natl Ctr Neurol & Psychiat, Neurol, Tokyo, Japan
[2] Natl Ctr Neurol & Psychiat, Multiple Sclerosis Ctr, Tokyo, Japan
[3] Natl Ctr Neurol & Psychiat, Natl Inst Neurosci, Immunol, Tokyo, Japan
来源：
MULTIPLE SCLEROSIS JOURNAL | 2018年 / 24卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
EP1600
引用
收藏
页码：903 / 904
页数：2
相关论文
共 50 条
  • [21] Glatiramer acetate for treatment of relapsing-remitting multiple sclerosis
    Johnson, Kenneth P.
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2012, 12 (04) : 371 - 384
  • [22] Lymphadenopathy in patients with multiple sclerosis undergoing treatment with glatiramer acetate
    Windhagen, A
    Maniak, S
    Marckmann, S
    Wilkening, A
    Lindert, RB
    Heidenreich, F
    Blasczyk, R
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2001, 70 (03): : 415 - 416
  • [23] The effect of glatiramer acetate treatment on axonal integrity in multiple sclerosis
    Narayanan, S
    Caramanos, Z
    Arnold, D
    MULTIPLE SCLEROSIS, 2004, 10 (7032): : S256 - S256
  • [24] Neuroprotection and glatiramer acetate: The possible role in the treatment of Multiple Sclerosis
    Ziemssen, T
    FRONTIERS IN CLINICAL NEUROSCIENCE: NEURODEGENERATION AND NEUROPROTECTION: A SYMPOSIUM IN ABEL LAJTHA'S HONOUR, 2004, 541 : 111 - 134
  • [25] Spasticity in multiple sclerosis: a pilot study to evaluate the efficacy of glatiramer acetate
    Meca-Lallana, Jose
    MULTIPLE SCLEROSIS, 2008, 14 : S165 - S165
  • [26] Long Term Treatment of Multiple Sclerosis with Glatiramer Acetate: Natural History of the Subtypes of Anti-Glatiramer Acetate Antibodies and Their Correlation with Clinical Efficacy
    Brenner, Talma
    Teitelbaum, Dvora
    Sicsic, Camille
    Karussis, Dimitrios
    NEUROLOGY, 2010, 74 (09) : A423 - A423
  • [27] Long-term treatment of multiple sclerosis with glatiramer acetate: Natural history of the subtypes of anti-glatiramer acetate antibodies and their correlation with clinical efficacy
    Karussis, Dimitros
    Teitelbaum, Dvora
    Sicsic, Camille
    Brenner, Talma
    JOURNAL OF NEUROIMMUNOLOGY, 2010, 220 (1-2) : 125 - 130
  • [28] Glatiramer Acetate (Copaxone®) in the Treatment of Relapsing/Remitting Cerebrospinal Multiple Sclerosis - Clinical Efficacy and Safety Profile
    Stourac, P.
    Praksova, P.
    Kontrova, I.
    Hladikova, M.
    Okacova, I.
    Benesova, Y.
    CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE, 2011, 74 (04) : 447 - 454
  • [29] Treatment with glatiramer acetate (Copaxone®) prevents neurodegeneration in patients with multiple sclerosis
    Jaworski, J.
    Leinhard, O. Dahlqvist
    Tisell, A.
    Lundberg, P.
    Landtblom, A. M.
    MULTIPLE SCLEROSIS, 2009, 15 (09): : S140 - S141
  • [30] Molecular profiling of glatiramer acetate early treatment effects in multiple sclerosis
    Anat, Achiron
    Anna, Feldman
    Michael, Gurevich
    DISEASE MARKERS, 2009, 27 (02) : 63 - 73
12345